229 related articles for article (PubMed ID: 21969814)
21. Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.
Botkjaer KA; Fogh S; Bekes EC; Chen Z; Blouse GE; Jensen JM; Mortensen KK; Huang M; Deryugina E; Quigley JP; Declerck PJ; Andreasen PA
Biochem J; 2011 Aug; 438(1):39-51. PubMed ID: 21635223
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Kobayashi H; Gotoh J; Hirashima Y; Fujie M; Sugino D; Terao T
J Biol Chem; 1995 Apr; 270(14):8361-6. PubMed ID: 7713945
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Tan X; Egami H; Nozawa F; Abe M; Baba H
Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
[TBL] [Abstract][Full Text] [Related]
24. Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination.
Juncker-Jensen A; Deryugina EI; Rimann I; Zajac E; Kupriyanova TA; Engelholm LH; Quigley JP
Cancer Res; 2013 Jul; 73(14):4196-211. PubMed ID: 23687338
[TBL] [Abstract][Full Text] [Related]
25. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration.
Legrand C; Polette M; Tournier JM; de Bentzmann S; Huet E; Monteau M; Birembaut P
Exp Cell Res; 2001 Apr; 264(2):326-36. PubMed ID: 11262189
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Suzuki M; Kobayashi H; Kanayama N; Saga Y; Suzuki M; Lin CY; Dickson RB; Terao T
J Biol Chem; 2004 Apr; 279(15):14899-908. PubMed ID: 14747469
[TBL] [Abstract][Full Text] [Related]
27. A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection.
Sanderson-Smith ML; Zhang Y; Ly D; Donahue D; Hollands A; Nizet V; Ranson M; Ploplis VA; Walker MJ; Castellino FJ
PLoS Pathog; 2013; 9(7):e1003469. PubMed ID: 23853591
[TBL] [Abstract][Full Text] [Related]
28. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
Demetriou MC; Pennington ME; Nagle RB; Cress AE
Exp Cell Res; 2004 Apr; 294(2):550-8. PubMed ID: 15023541
[TBL] [Abstract][Full Text] [Related]
29. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H
Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419
[TBL] [Abstract][Full Text] [Related]
30. Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Obermajer N; Doljak B; Kos J
Mol Cancer; 2009 Oct; 8():88. PubMed ID: 19845941
[TBL] [Abstract][Full Text] [Related]
31. Borrelia burgdorferi induces secretion of pro-urokinase-type plasminogen activator by human monocytes.
Fuchs H; Simon MM; Wallich R; Bechtel M; Kramer MD
Infect Immun; 1996 Oct; 64(10):4307-12. PubMed ID: 8926103
[TBL] [Abstract][Full Text] [Related]
32. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.
Casar B; Rimann I; Kato H; Shattil SJ; Quigley JP; Deryugina EI
Oncogene; 2014 Jan; 33(2):255-68. PubMed ID: 23208492
[TBL] [Abstract][Full Text] [Related]
33. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.
Isaksson GL; Hinrichs GR; Andersen H; Bach ML; Weyer K; Zachar R; Henriksen JE; Madsen K; Lund IK; Mollet G; Bistrup C; Birn H; Jensen BL; Palarasah Y
J Am Soc Nephrol; 2024 Apr; 35(4):410-425. PubMed ID: 38254266
[TBL] [Abstract][Full Text] [Related]
34. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Swiercz R; Keck RW; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2001; 8(3):463-70. PubMed ID: 11295064
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.
Stewart AG; Xia YC; Harris T; Royce S; Hamilton JA; Schuliga M
Br J Pharmacol; 2013 Dec; 170(7):1421-35. PubMed ID: 24111848
[TBL] [Abstract][Full Text] [Related]
36. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
37. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V
J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
[TBL] [Abstract][Full Text] [Related]
38. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
39. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
[TBL] [Abstract][Full Text] [Related]
40. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
